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a  b  s  t  r  a  c  t
We  present  two patients  with  a clinically  suspected  neuroendocrine  tumor  who  underwent 68Ga-DOTA-
NOC  PET/CT  where  a high  tracer  uptake  in  the uncinate  process  was  observed.  Repeated  endoscopic
ultrasound  was  negative  for  a neuroendocrine  tumor. 68Ga-DOTA  peptide  techniques  have  emerged  as
more  sensitive  and  speciﬁc  tests  than  Octreoscan®. Nevertheless,  physiological  uptake  of  the  uncinate
process  remains  a “false”  positive  source  and  should  be  considered  when  managing  patients  with  clini-
cally  suspected  neuroendocrine  tumors.  Endoscopic  ultrasound  is a useful  technique  in this  setting  given
its  high  diagnostic  accuracy  for pancreatic  nodules  as small  as  2 mm.
© 2015 Sociedade  Portuguesa  de  Endocrinologia,  Diabetes  e Metabolismo.  Published  by Elsevier
España,  S.L.U.  This  is an  open  access  article  under  the CC BY-NC-ND  license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Falsos  positivos  em  estudos 68Ga-DOTA-NOC:  papel  da  ecoendoscopia
alavras-chave:
umor neuroendócrino pancreático
8GaDOTA-NOC PET/CT
coendoscopia
r  e  s  u  m  o
Os autores  apresentam  2 doentes  com  suspeita  clínica  de  tumor  neuroendócrino.  No  decurso  da
investigac¸ ão realizaram  PET/TC  com 68Ga-DOTA-NOC  que  revelou  captac¸ ão  aumentada  no  processo  unci-
nado.  Ecoendoscopias  seriadas  não  identiﬁcaram  qualquer  lesão  pancreática.  As técnicas  de  medicina
nuclear  com  utilizac¸ ão  de  péptidos 68Ga-DOTA  têm  emergido  como  exames  mais  sensíveis  e especíﬁcos
que  o tradicional  Octreoscan®. Contudo,  a  hipercaptac¸ ão ﬁsiológica  do  processo  uncinado  mantém-se
uma  fonte  de “falsos”  positivos  que deve  ser  considerada  na  abordagem  de  doentes  com  suspeita  clínica
de tumor  neuroendócrino.  A  ecoendoscopia  é uma  técnica  útil  neste  contexto  dada  a  elevada  acuidade
no  diagnóstico  de  nódulos  pancreáticos,  permitindo  observar  lesões  a partir  de  2 mm.
©  2015  Sociedade  Portuguesa  de  Endocrinologia,  Diabetes  e Metabolismo.  Publicado  por  Elsevier
España,  S.L.U.  Este  é um  artigo  Open  Access  sob  a licença  de  CC BY-NC-ND
(http://creativecommons.org/licenses/by-nc-nd/4.0/).We  present two patients with a clinically suspected neu-
oendocrine tumor (NET) who underwent 68Ga-DOTA-NOC and
ndoscopic ultrasound (EUS).
The ﬁrst case refers to a 49-year-old woman who presented
ith Cushingoid features for two years, namely easy bruising,
roximal myopathy, hyperpigmentation, new-onset hyperten-
ion, weight gain, depression and emotional lability. Laboratory
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icense  (http://creativecommons.org/licenses/by-nc-nd/4.0/).evaluation revealed ACTH dependent hypercortisolism (urinary
free cortisol 227 g/24 h – R 20–90; ACTH 91.1 – R <50 pg/mL).
CRH test, high dexamethasone suppression test and CRH stim-
ulated bilateral inferior petrosal sinus sampling supported an
ectopic source of ACTH. Brain MRI  revealed a normal pituitary
gland. Metyrapone (up to 1.75 g/day) and ketoconazole (up to
800 mg/day) were started, but 9 months later the patient was sub-
mitted to a bilateral adrenalectomy due to intolerance to medical
therapy and worsening of medical comorbidities. In the diagnos-
tic workup a 68Ga-DOTA-NOC PET/CT was performed and revealed
a high tracer uptake (maximum SUV (standardized uptake value)
ished  by  Elsevier  España,  S.L.U.  This  is  an  open  access  article  under  the  CC  BY-NC-ND
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tFig. 1. 68Ga-DOTA-NOC PET/CT: (a) PET positive uptake in the uncinate process, 
7.35) in the uncinate process (Fig. 1a–c). The EUS examination
UCT 10–140 AL5; Olympus) only depicted a 6 mm well-deﬁned
yst in the pancreatic head (Fig. 2). Despite the benign characteris-
ics of the cyst a ﬁne needle aspiration was taken with a 25G needle
o rule out an atypical NET. Cell block cytology was consistent with
 simple cyst. The patient repeated EUS one year later and aside
rom the pancreatic cyst no other abnormalities were seen. Five
ears post-adrenalectomy a pituitary macroadenoma was depicted
n brain MRI. Transsphenoidal surgery was performed and patho-
ogic examination revealed an ACTH-staining tumor. Serum ACTH
ramatically decreased after surgery (31 pg/mL).
In the second case a 38-year-old man  presented with aque-
us chronic diarrhea, arthralgia and episodic palpitations for 1
ear. Clinical suspicious of a NET led to biochemical work-up and
unctional imaging (Octreoscan®). Levels of 24 h urinary 5-HIAA,
erum chromogranin A and neuron-speciﬁc enolase were nor-
al. Octreoscan® revealed a moderate-high tracer uptake in the
pper abdomen. Subsequently, a 68Ga-DOTA-NOC PET/CT showed
 high uptake (maximum SUV 21.7) in the uncinate process. The
ig. 2. Linear endoscopic ultrasound: (a) 6 mm pancreatic head cyst; (b) normal
ncinate process (UNC) underlined by the superior mesenteric vein (SMV) as seen
hrough D2.
1
2um SUV 17.35; (b) anatomical location in CT scan; (c) composed PET/CT image.
patient underwent two  EUS examinations, requested by the attend-
ing physician 8 months apart, and no pancreatic abnormality was
identiﬁed. On follow-up the patient was diagnosed with an anxiety
disorder and the symptoms improved after commencing psychi-
atric therapy.
NETs are rare and heterogeneous tumors that arise most
frequently in the gastrointestinal tract and bronchopulmonary
system. Evaluation of NET of unknown origin includes a thorough
family history, tumor markers, chest, abdomen and pelvis CT
or MRI  and nuclear imaging techniques.1 Currently, 68Ga-DOTA
peptides techniques are replacing Octreoscan® as the standard
nuclear imaging technique to assess NET.2 Pancreatic head uptake
of 68Ga-DOTA peptides is common in PET/CT. Although most
patients present low uptake in the pancreatic head, a high focal
uptake in the uncinate process, mimicking a malignant tumor, can
be physiological, with maximum reported SUV up to 28.7.3,4
The presented cases stress the importance of carefully interpret-
ing nuclear imaging positive ﬁndings in the uncinate pancreatic
process where, even with a more sensible and speciﬁc method such
as 68Ga-DOTA-NOC PET/CT, physiological high uptake can occur
and is responsible for “false” positive results. Also, after a positive
nuclear imaging test, EUS is a reliable technique to diagnose or
rule out a pancreatic NET given its high diagnostic accuracy even
for pancreatic lesions as small as 2–3 mm.5
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